Charles Schwab Investment Management Inc. Invests $2.50 Million in CeriBell (NASDAQ:CBLL)

Charles Schwab Investment Management Inc. acquired a new stake in shares of CeriBell (NASDAQ:CBLL) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 96,582 shares of the company’s stock, valued at approximately $2,500,000.

Separately, Rhumbline Advisers acquired a new position in CeriBell during the 4th quarter valued at about $320,000.

CeriBell Stock Down 1.9 %

CBLL stock opened at $19.46 on Friday. CeriBell has a one year low of $18.69 and a one year high of $32.75. The firm’s 50-day moving average price is $22.33.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. Sell-side analysts predict that CeriBell will post -2.46 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on CBLL. TD Cowen increased their price target on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Canaccord Genuity Group reissued a “buy” rating and issued a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell presently has a consensus rating of “Buy” and a consensus price target of $32.60.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.